Clinical Research Directory

Inclusion Criteria: 1. Male or female participants ≥ 18 years old. 2. Diagnosis of NMO or NMOSD. 3. Anti-AQP4 antibody seropositive. 4. Historical relapse of at least 1 relapses in the last 12 months or 2 relapses in the last 24 months with at least 1 relapse in the 12 months prior to the screening. 5. Expanded Disability Status Scale score ≤ 7.5. 6. Patients must give written informed consent. Exclusion Criteria: 1. Use of intravenous steroid pulse therapy or intravenous immunoglobulin or plasma exchange/adsorption within 3 weeks prior to Screening. 2. Use of tocilizumab, satralizumab, belimumab, ofatumumab within 1 months prior to Screening. 3. Patients treated with oral immunosuppressive agents other than steroids (e.g. azathioprine, mycophenolate mofetil, methotrexate, tacrolimus, cyclosporine in the 3 months prior to allocation. 4. Use of rituximab or inebilizumab within 6 months prior to Screening. 5. Patients infected with hepatitis B or C virus, or human immunodeficiency virus, or those having active infectious diseases. 6. Patients with a severe chronic infection or a history of recurrent infections. 7. Patients with a history of radiation treatment (whole body irradiation or lymphoid irradiation) or stem cell transplantation. 8. Patients who are pregnant or breast-feeding. 9. Patients who are participating in other clinical trials for NMOSD. 10. Patients diagnosed with cancer.